Legalize / European Union / Delegated Regulation

Commission Delegated Regulation (EU) 2021/849 of 11 March 2021 amending, for the purposes of its adaptation to technical and scientific progress, Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)

Type Delegated Regulation

Publication 2021-05-28

State In force

Text As published

Department European Commission, ENV

Source EUR-Lex

articles 2

This is the act as published. Later amendments are not folded into the text below: each one is a separate act in this repository and an entry in this law's history.

Reform history JSON API


28.5.2021	EN	Official Journal of the European Union	L 188/27

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 ¹, and in particular Article 37(5) thereof,

Whereas:

(1) Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation.

(2) Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (‘Agency’) pursuant to Article 37 of Regulation (EC) No 1272/2008. The Committee for Risk Assessment of the Agency (RAC) adopted opinions ² on those proposals, after having taken account of the comments received from the parties concerned. Those RAC opinions are:

— Opinion of 15 March 2019 concerning 1,2,4-triazole,

— Opinion of 15 March 2019 concerning 1,4-dioxane,

— Opinion of 15 March 2019 concerning benzyl salicylate,

— Opinion of 15 March 2019 concerning flumioxazin (ISO),

— Opinion of 15 March 2019 concerning mancozeb (ISO),

— Opinion of 15 March 2019 concerning M-factors for long-term aquatic hazard for the copper substances listed in Commission Regulation (EU) 2016/1179,

— Opinion of 15 March 2019 concerning N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane,

— Opinion of 15 March 2019 concerning N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen,

— Opinion of 15 March 2019 concerning p-cymene; 1-isopropyl-4-methylbenzene,

— Opinion of 15 March 2019 concerning p-mentha-1,3-diene; alpha-terpinene; 1-isopropyl-4-methylcyclohexa-1,3-diene,

— Opinion of 15 March 2019 concerning prothioconazole,

— Opinion of 15 March 2019 concerning (R)-p-mentha-1,8-diene; d-limonene,

— Opinion of 15 March 2019 concerning thiophanate-methyl,

— Opinion of 15 March 2019 concerning tolclofos-methyl (ISO); O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate,

— Opinion of 15 March 2019 concerning tolpyralate,

— Opinion of 15 March 2019 concerning trinickel disulphide,

— Opinion of 13 June 2019 concerning azamethiphos,

— Opinion of 13 June 2019 concerning 2-phenoxyethanol,

— Opinion of 13 June 2019 concerning 2,2-dibromo-2-cyanoacetamide,

— Opinion of 13 June 2019 concerning 3-aminomethyl-3,5,5-trimethylcyclohexylamine,

— Opinion of 13 June 2019 concerning 6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol,

— Opinion of 13 June 2019 concerning diflufenican (ISO) N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide,

— Opinion of 13 June 2019 concerning imidacloprid (ISO); 1-(6-chloropyridin-3-ylmethyl)-N-nitroimidazolidin-2-ylidenamine,

— Opinion of 13 June 2019 concerning pyriofenone,

— Opinion of 13 June 2019 concerning S-abscisic acid,

— Opinion of 13 June 2019 concerning tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate,

— Opinion of 20 September 2019 concerning 1,2-epoxy-4-epoxyethylcyclohexane,

— Opinion of 20 September 2019 concerning 4-methylpentan-2-one,

— Opinion of 20 September 2019 concerning boric acid; diboron trioxide; tetraboron disodium heptaoxide hydrate; disodium tetraborate anhydrous; orthoboric acid sodium salt; disodium tetraborate decahydrate; disodium tetraborate pentahydrate,

— Opinion of 20 September 2019 concerning citric acid,

— Opinion of 20 September 2019 concerning clomazone,

— Opinion of 20 September 2019 concerning desmedipham,

— Opinion of 20 September 2019 concerning dimethomorph,

— Opinion of 20 September 2019 concerning emamectin benzoate,

— Opinion of 20 September 2019 concerning esfenvalerate (ISO) (S)-α-cyano-3-phenoxybenzyl (S)-2-(4-chlorophenyl)-3-methylbutyrate,

— Opinion of 20 September 2019 concerning ethametsulfuron-methyl (ISO),

— Opinion of 20 September 2019 concerning mecoprop-P (ISO); (R)-2-(4-chloro-2-methylphenoxy)propionic acid and its salts,

— Opinion of 20 September 2019 concerning methyl salicylate,

— Opinion of 20 September 2019 concerning phenmedipham (ISO),

— Opinion of 20 September 2019 concerning trifloxystrobin (ISO),

— Opinion of 20 September 2019 concerning triticonazole,

— Opinion of 5 December 2019 concerning 1,4-dimethylnaphthalene,

— Opinion of 5 December 2019 concerning (3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide,

— Opinion of 5 December 2019 concerning 3-methylpyrazole,

— Opinion of 5 December 2019 concerning carbendazim (ISO); methyl benzimidazol-2-ylcarbamate,

— Opinion of 5 December 2019 concerning cypermethrin cis/trans +/- 40/60; (RS)-α-cyano-3-phenoxybenzyl (1RS,3RS;1RS,3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate,

— Opinion of 5 December 2019 concerning imazamox (ISO); (RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid,

— Opinion of 5 December 2019 concerning tetrafluoroethylene,

— Opinion of 5 December 2019 concerning thiamethoxam (ISO); 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine,

— Opinion of 5 December 2019 concerning trinexapac-ethyl (ISO); ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate.

(3) Acute Toxicity Estimates (ATE) are mainly used to determine the classification for human health acute toxicity of mixtures containing substances classified for acute toxicity. The inclusion of harmonised ATE values in the entries listed in Annex VI to Regulation (EC) No 1272/2008 facilitates the harmonisation of the classification of mixtures and provides support for enforcement authorities. Following further scientific assessmentsof some substances, ATE values have been derived by the Agency for dicopper oxide, dicopper chloride trihydroxide, tetracopper hexahydroxide sulphate and tetracopper hexahydroxide sulphate hydrate, copper flakes (coated with aliphatic acid), copper(II) carbonate--copper(II) hydroxide (1:1), copper dihydroxide; copper(II) hydroxide, bordeaux mixture; reaction products of copper sulphate with calcium dihydroxide and copper sulphate pentahydrate, in addition to those proposed in the RAC opinions for other substances. Those ATE values should be inserted in the penultimate column of Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008.

(4) Additional information was received by the Commission contesting the scientific assessment set out in the RAC opinions of 15 March 2019 concerning mancozeb, of 20 September 2019 concerning 4-methylpentan-2-one, and of 20 September 2019 concerning dimethomorph. That information was assessed by the Commission and was not found sufficient to cast doubts on the scientific analysis contained in the RAC opinions.

(5) The Commission therefore considers appropriate to introduce, update or delete the harmonised classification and labelling of certain substances.

(6) Regulation (EC) No 1272/2008 should therefore be amended accordingly.

(7) Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or revised classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Such requirements may include those set out in point (f) of Article 22(1) of Regulation (EC) No 1907/2006 of the European Parliament and of the Council ³ or those set out in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council ⁴. Suppliers should, however, have the possibility to apply the new or updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of this Regulation and as of the date of entry into force to ensure a high level of protection of human health and of the environment and to provide sufficient flexibility to suppliers,

HAS ADOPTED THIS REGULATION:

Article 1

Amendments to Regulation (EC) No 1272/2008

Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

Article 2

Entry into force and application

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

It shall apply from 17 December 2022.

By way of derogation from the second paragraph of this Article, substances and mixtures may be classified, labelled and packaged in accordance with this Regulation from its date of entry into force.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 11 March 2021.

For the Commission

The President

Ursula VON DER LEYEN

OJ L 353, 31.12.2008, p. 1.

The opinions are accessible via the following website:https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).

Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ L 167, 27.6.2012, p. 1).

ANNEX

In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:

(1) the following entries are inserted:

Index No	Chemical Name	EC No	CAS No	Classification	Classification	Labelling	Labelling	Labelling	Specific Conc. Limits, M- factors and ATE	Notes
Index No	Chemical Name	EC No	CAS No	Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)	Specific Conc. Limits, M- factors and ATE	Notes
‘601-093-00-6	1,4-dimethylnaphthalene	209-335-9	571-58-4	Acute Tox. 4 Asp. Tox. 1 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 3	H302 H304 H319 H400 H412	GHS07 GHS08 GHS09 Dgr	H302 H304 H319 H410		oral: ATE = 1 300 mg/kg bw M = 1’
‘601-094-00-1	1-isopropyl-4-methylbenzene; p-cymene	202-796-7	99-87-6	Flam. Liq. 3 Acute Tox. 3 Asp. Tox. 1 Aquatic Chronic 2	H226 H331 H304 H411	GHS02 GHS06 GHS08 GHS09 Dgr	H226 H331 H304 H411		inhalation: ATE = 3 mg/l (vapours)’
‘601-095-00-7	p-mentha-1,3-diene; 1-isopropyl-4-methylcyclohexa-1,3-diene; alpha-terpinene	202-795-1	99-86-5	Flam. Liq. 3 Acute Tox. 4 Skin Sens. 1 Asp. Tox. 1 Aquatic Chronic 2	H226 H302 H317 H304 H411	GHS02 GHS07 GHS08 GHS09 Dgr	H226 H302 H317 H304 H411		oral: ATE = 1 680 mg/kg bw’
‘602-110-00-X	tetrafluoroethylene	204-126-9	116-14-3	Carc. 1B	H350	GHS08 Dgr	H350’
‘604-095-00-5	6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol; [DBMC]	204-327-1	119-47-1	Repr. 1B	H360F	GHS08 Dgr	H360F’
‘606-152-00-X	(5-chloro-2-methoxy-4-methyl-3-pyridyl)(4,5,6-trimethoxy-o-tolyl)methanone; pyriofenone	-	688046-61-9	Carc. 2 Aquatic Chronic 1	H351 H410	GHS08 GHS09 Wng	H351 H410		M = 1’
‘607-747-00-7	2,2-dibromo-2-cyanoacetamide; [DBNPA]	233-539-7	10222-01-2	Acute Tox. 2 Acute Tox. 3 STOT RE 1 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H330 H301 H372 (respiratory tract) (inhalation) H315 H318 H317 H400 H410	GHS06 GHS08 GHS05 GHS09 Dgr	H330 H301 H372 (respiratory tract) (inhalation) H315 H318 H317 H410		inhalation: ATE = 0,24 mg/l (dusts or mists) oral: ATE = 118 mg/kg bw M = 1 M = 1’
‘607-748-00-2	[S-(Z,E)]-5-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)-3-methylpenta-2,4-dienoic acid; S-abscisic acid	244-319-5	21293-29-8	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 1 M = 1’
‘607-749-00-8	methyl salicylate	204-317-7	119-36-8	Repr. 2 Acute Tox. 4 Skin Sens. 1B Aquatic Chronic 3	H361d H302 H317 H412	GHS07 GHS08 Wng	H361d H302 H317 H412		oral: ATE = 890 mg/kg bw’
‘607-750-00-3	citric acid	201-069-1	77-92-9	Eye Irrit. 2 STOT SE 3	H319 H335	GHS07 Wng	H319 H335’
‘607-751-00-9	ethametsulfuron-methyl (ISO); methyl 2-({[4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)benzoate	-	97780-06-8	Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H319 H400 H410	GHS07 GHS09 Wng	H319 H410		M = 1 000 M = 100’
‘607-752-00-4	trinexapac-ethyl (ISO); ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate	-	95266-40-3	STOT RE 2 Skin Sens. 1B Aquatic Chronic 1	H373 (gastrointestinal tract) H317 H410	GHS08 GHS07 GHS09 Wng	H373 (gastrointestinal tract) H317 H410		M = 1’
‘607-753-00-X	(3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide	-	78821-43-9	Aquatic Chronic 4	H413		H413’
‘607-754-00-5	benzyl salicylate	204-262-9	118-58-1	Skin Sens. 1B	H317	GHS07 Wng	H317’
‘607-755-00-0	(RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate; tolpyralate	-	1101132-67-5	Carc. 2 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H361fd H373 (eye) H400 H410	GHS08 GHS09 Wng	H351 H361fd H373 (eye) H410		M = 10 M = 100’
‘613-337-00-9	prothioconazole (ISO); 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione	-	178928-70-6	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 10 M = 1’
‘613-338-00-4	azamethiphos (ISO); S-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl] O,O-dimethyl thiophosphate	252-626-0	35575-96-3	Carc. 2 Acute Tox. 3 Acute Tox. 4 STOT SE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H351 H331 H302 H370 (nervous system) H317 H400 H410	GHS06 GHS08 GHS09 Dgr	H351 H331 H302 H370 (nervous system) H317 H410		inhalation: ATE = 0,5 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 1 000 M = 1 000 ’
‘613-339-00-X	3-methylpyrazole	215-925-7	1453-58-3	Repr. 1B Acute Tox. 4 STOT RE 2 Skin Corr. 1 Eye Dam. 1	H360D H302 H373 (lung) H314 H318	GHS08 GHS07 GHS05 Dgr	H360D H302 H373 (lung) H314		oral: ATE = 500 mg/kg bw’
‘613-340-00-5	clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one	-	81777-89-1	Acute Tox. 4 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1	H332 H302 H400 H410	GHS07 GHS09 Wng	H332 H302 H410		inhalation: ATE = 4,85 mg/l (dusts or mists) oral: ATE = 768 mg/kg bw M = 1 M = 1’
‘614-030-00-2	emamectin benzoate (ISO); (4"R)-4"-deoxy-4"-(methylamino) avermectin B1 benzoate	-	155569-91-8	Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 STOT SE 1 STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H331 H311 H301 H370 (nervous system) H372 (nervous system) H318 H400 H410	GHS06 GHS05 GHS08 GHS09 Dgr	H331 H311 H301 H370 (nervous system) H372 (nervous system) H318 H410		inhalation: ATE = 0,663 mg/l (dusts or mists) dermal: ATE = 300 mg/kg bw oral: ATE = 60 mg/kg bw STOT RE 1; H372: C ≥ 5 %; STOT RE 2; H373: 0,5 % ≤ C < 5 % M = 10 000 M = 10 000 ’
‘616-234-00-7	N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen	-	1228284-64-7	Carc. 2 Repr. 2 Aquatic Acute 1 Aquatic Chronic 1	H351 H361f H400 H410	GHS08 GHS09 Wng	H351 H361f H410		M = 1 M = 1’
‘616-235-00-2	N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane	-	874967-67-6	Carc. 2 Aquatic Acute 1 Aquatic Chronic 2	H351 H400 H411	GHS08 GHS09 Wng	H351 H410		M = 1’

(2) the entries corresponding to index numbers 005-007-00-2; 005-008-00-8; 005-011-00-4; 005-011-01-1; 005-011-02-9; 006-069-00-3; 006-076-00-1; 015-113-00-0; 028-007-00-4; 029-002-00-X; 029-015-00-0; 029-016-00-6; 029-017-00-1; 029-018-00-7; 029-019-01-X; 029-020-00-8; 029-021-00-3; 029-022-00-9; 029-023-00-4; 601-029-00-7; 601-096-00-2; 603-024-00-5; 603-066-00-4; 603-098-00-9; 606-004-00-4; 607-421-00-4; 607-424-00-0; 607-434-00-5; 608-058-00-4; 612-067-00-9; 612-252-00-4; 613-048-00-8; 613-102-00-0; 613-111-00-X; 613-166-00-X; 613-208-00-7; 613-267-00-9; 613-282-00-0; 616-032-00-9; 616-106-00-0 and 616-113-00-9 are replaced by the following entries respectively:

Index No	Chemical Name	EC No	CAS No	Classification	Classification	Labelling	Labelling	Labelling	Specific Conc. Limits, M- factors and ATE	Notes
Index No	Chemical Name	EC No	CAS No	Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)	Specific Conc. Limits, M- factors and ATE	Notes
‘005-007-00-2	boric acid [1] boric acid [2]	233-139-2 [1] 234-343-4 [2]	10043-35-3 [1] 11113-50-1 [2]	Repr. 1B	H360FD	GHS08 Dgr	H360FD’
‘005-008-00-8	diboron trioxide	215-125-8	1303-86-2	Repr. 1B	H360FD	GHS08 Dgr	H360FD’
‘005-011-00-4	tetraboron disodium heptaoxide, hydrate; [1] disodium tetraborate, anhydrous; [2] orthoboric acid, sodium salt [3] disodium tetraborate decahydrate [4] disodium tetraborate pentahydrate [5]	235-541-3 [1] 215-540-4 [2] 237-560-2 [3] 215-540-4 [4] 215-540-4 [5]	12267-73-1 [1] 1330-43-4 [2] 13840-56-7 [3] 1303-96-4 [4] 12179-04-3 [5]	Repr. 1B	H360FD	GHS08 Dgr	H360FD’


‘006-069-00-3	thiophanate-methyl (ISO); dimethyl (1,2-phenylenedicarbamothioyl)biscarbamate; dimethyl 4,4′-(o-phenylene)bis(3-thioallophanate)	245-740-7	23564-05-8	Carc. 2 Muta. 2 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H351 H341 H332 H317 H400 H410	GHS08 GHS07 GHS09 Wng	H351 H341 H332 H317 H410		inhalation: ATE = 1,7 mg/l (dusts and mists) M = 10 M = 10’
‘006-076-00-1	mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt	-	8018-01-7	Carc. 2 Repr. 1B STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H351 H360D H373 (thyroid, nervous system) H317 H400 H410	GHS08 GHS07 GHS09 Dgr	H351 H360D H373 (thyroid, nervous system) H317 H410		M = 10 M = 10’
‘015-113-00-0	tolclofos-methyl (ISO); O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate	260-515-3	57018-04-9	Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		M = 1 M = 1’
‘028-007-00-4	trinickel disulfide; nickel subsulfide; [1] heazlewoodite [2]	234-829-6 [1] - [2]	12035-72-2 [1] 12035-71-1 [2]	Carc. 1A Muta. 2 Acute Tox. 3 STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H350i H341 H331 H372** H317 H400 H410	GHS08 GHS06 GHS09 Dgr	H350i H341 H331 H372** H317 H410		inhalation: ATE = 0,92 mg/l (dusts or mists)’
‘029-002-00-X	dicopper oxide; copper (I) oxide	215-270-7	1317-39-1	Acute Tox. 4 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H332 H302 H318 H400 H410	GHS07 GHS05 GHS09 Dgr	H332 H302 H318 H410		inhalation: ATE = 3,34 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 100 M = 10’
‘029-015-00-0	copper thiocyanate	214-183-1	1111-67-7	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410	EUH032	M = 10 M = 10’
‘029-016-00-6	copper(II) oxide	215-269-1	1317-38-0	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 100 M = 10’
‘029-017-00-1	dicopper chloride trihydroxide	215-572-9	1332-65-6	Acute Tox. 4 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1	H332 H301 H400 H410	GHS06 GHS09 Dgr	H332 H301 H410		inhalation: ATE = 2,83 mg/l (dusts or mists) oral: ATE = 299 mg/kg bw M = 10 M = 10’
‘029-018-00-7	tetracopper hexahydroxide sulphate; [1] tetracopper hexahydroxide sulphate hydrate [2]	215-582-3 [1] 215-582-3 [2]	1333-22-8 [1] 12527-76-3 [2]	Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1	H302 H400 H410	GHS07 GHS09 Wng	H302 H410		oral: ATE = 500 mg/kg bw M = 10 M = 10’
‘029-019-01-X	copper flakes (coated with aliphatic acid)	-	-	Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H331 H302 H319 H400 H410	GHS06 GHS09 Dgr	H331 H302 H319 H410		inhalation: ATE = 0,733 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 10’
‘029-020-00-8	copper(II) carbonate—copper(II) hydroxide (1:1)	235-113-6	12069-69-1	Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H332 H302 H319 H400 H410	GHS07 GHS09 Wng	H332 H302 H319 H410		inhalation: ATE = 1,2 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 10’
‘029-021-00-3	copper dihydroxide; copper(II) hydroxide	243-815-9	20427-59-2	Acute Tox. 2 Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H330 H302 H318 H400 H410	GHS06 GHS05 GHS09 Dgr	H330 H302 H318 H410		inhalation: ATE = 0,47 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 10’
‘029-022-00-9	bordeaux mixture; reaction products of copper sulphate with calcium dihydroxide	-	8011-63-0	Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H332 H318 H400 H410	GHS07 GHS05 GHS09 Dgr	H332 H318 H410		inhalation: ATE = 1,97 mg/l (dusts or mists) M = 10 M = 1’
‘029-023-00-4	copper sulphate pentahydrate	231-847-6	7758-99-8	Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H302 H318 H400 H410	GHS07 GHS05 GHS09 Dgr	H302 H318 H410		oral: ATE = 481 mg/kg bw M = 10 M = 1’
‘601-029-00-7	dipentene; limonene [1] (S)-p-mentha-1,8-diene; l-limonene [2] trans-1-methyl-4-(1-methylvinyl)cyclohexene; [3] (±)-1-methyl-4-(1-methylvinyl)cyclohexene [4]	205-341-0 [1] 227-815-6 [2] 229-977-3 [3] 231-732-0 [4]	138-86-3 [1] 5989-54-8 [2] 6876-12-6 [3] 7705-14-8 [4]	Flam. Liq. 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H226 H315 H317 H400 H410	GHS02 GHS07 GHS09 Wng	H226 H315 H317 H410			C’
‘601-096-00-2	(R)-p-mentha-1,8-diene; d-limonene	227-813-5	5989-27-5	Flam. Liq. 3 Skin Irrit. 2 Skin Sens. 1B Asp. Tox. 1 Aquatic Acute 1 Aquatic Chronic 3	H226 H315 H317 H304 H400 H412	GHS02 GHS07 GHS08 GHS09 Dgr	H226 H315 H317 H304 H410		M = 1’
‘603-024-00-5	1,4-dioxane	204-661-8	123-91-1	Flam. Liq. 2 Carc. 1B STOT SE 3 Eye Irrit. 2	H225 H350 H335 H319	GHS02 GHS08 GHS07 Dgr	H225 H350 H335 H319	EUH019 EUH066		D’
‘603-066-00-4	7-oxa-3-oxiranylbicyclo[4.1.0]heptane; 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide	203-437-7	106-87-6	Carc. 1B Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4	H350 H341 H360F H331 H302	GHS08 GHS06 Dgr	H350 H341 H360F H331 H302		inhalation: ATE = 0,5 mg/l (dusts or mists) oral: ATE = 1 847 mg/kg bw’
‘603-098-00-9	2-phenoxyethanol	204-589-7	122-99-6	Acute Tox. 4 STOT SE 3 Eye Dam. 1	H302 H335 H318	GHS05 GHS07 Dgr	H302 H335 H318		oral: ATE = 1 394 mg/kg bw’
‘606-004-00-4	4-methylpentan-2-one; isobutyl methyl ketone	203-550-1	108-10-1	Flam. Liq. 2 Carc. 2 Acute Tox. 4 STOT SE 3 Eye Irrit. 2	H225 H351 H332 H336 H319	GHS02 GHS07 GHS08 Dgr	H225 H351 H332 H336 H319	EUH066	inhalation: ATE = 11 mg/l (vapours)’
‘607-421-00-4	cypermethrin (ISO); α-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; cypermethrin cis/trans +/- 40/60	257-842-9	52315-07-8	Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1	H332 H302 H335 H373 (nervous system) H400 H410	GHS07 GHS08 GHS09 Wng	H332 H302 H335 H373 (nervous system) H410		oral; ATE = 500 mg/kg bw inhalation; ATE = 3,3 mg/l (dusts or mists) M = 100000 M = 100000’
‘607-424-00-0	trifloxystrobin (ISO); methyl (E)-methoxyimino-{(E)-α-[1-(α,α,α-trifluoro-m-tolyl)ethylideneaminooxy]-o-tolyl}acetate	-	141517-21-7	Lact. Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H362 H317 H400 H410	GHS07 GHS09 Wng	H362 H317 H410		M = 100 M = 10’
‘607-434-00-5	mecoprop-P (ISO) [1] and its salts; (R)-2-(4-chloro-2-methylphenoxy)propionic acid [1] and its salts	240-539-0 [1]	16484-77-8 [1]	Acute Tox. 4 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1	H302 H318 H400 H410	GHS07 GHS05 GHS09 Dgr	H302 H318 H410		oral: ATE = 431 mg/kg bw M = 10 M = 10’
‘608-058-00-4	esfenvalerate (ISO); (S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate	-	66230-04-4	Acute Tox. 3 Acute Tox. 3 STOT SE 1 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H331 H301 H370 (nervous system) H373 H317 H400 H410	GHS06 GHS08 GHS09 Dgr	H331 H301 H370 (nervous system) H373 H317 H410		oral; ATE = 88,5 mg/kg bw inhalation; ATE = 0,53 mg/l (dusts or mists) M = 10 000 M = 10 000 ’
‘612-067-00-9	3-aminomethyl-3,5,5-trimethylcyclohexylamine	220-666-8	2855-13-2	Acute Tox. 4 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1A	H302 H314 H318 H317	GHS05 GHS07 Dgr	H302 H314 H317		oral: ATE = 1 030 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,001 %’
‘612-252-00-4	imidacloprid (ISO); (E)-1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolidin-2-ylideneamine; (2E)-1-[(6-chloropyridin-3-yl) methyl]-N-nitroimidazolidin-2-imine	428-040-8	138261-41-3	Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1	H301 H400 H410	GHS06 GHS09 Dgr	H301 H410		oral: ATE = 131 mg/kg bw M = 100 M = 1 000 ’
‘613-048-00-8	carbendazim (ISO); methyl benzimidazol-2-ylcarbamate	234-232-0	10605-21-7	Muta. 1B Repr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H340 H360FD H317 H400 H410	GHS07 GHS08 GHS09 Dgr	H340 H360FD H317 H410		M = 10 M = 10’
‘613-102-00-0	dimethomorph (ISO); (E,Z)-4-(3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)acryloyl)morpholine	404-200-2	110488-70-5	Repr. 1B Aquatic Chronic 2	H360F H411	GHS08 GHS09 Dgr	H360F H411’
‘613-111-00-X	1,2,4-triazole	206-022-9	288-88-0	Repr. 1B Acute Tox. 4 Eye Irrit. 2	H360FD H302 H319	GHS08 GHS07 Dgr	H360FD H302 H319		oral: ATE = 1 320 mg/kg bw’
‘613-166-00-X	flumioxazin (ISO); N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)cyclohex-1-ene-1,2-dicarboximide	-	103361-09-7	Repr. 2 Aquatic Acute 1 Aquatic Chronic 1	H361d H400 H410	GHS08 GHS09 Wng	H361d H410		M = 1 000 M = 1 000 ’
‘613-208-00-7	imazamox (ISO); (RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid	-	114311-32-9	Repr. 2 Aquatic Acute 1 Aquatic Chronic 1	H361d H400 H410	GHS08 GHS09 Wng	H361d H410		M = 10 M = 10’
‘613-267-00-9	thiamethoxam (ISO); 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine	428-650-4	153719-23-4	Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1	H361fd H302 H400 H410	GHS07 GHS08 GHS09 Wng	H361fd H302 H410		oral: ATE = 780 mg/kg bw M = 10 M = 10’
‘613-282-00-0	triticonazole (ISO); (RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol	-	138182-18-0	Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1	H361f H373 H400 H410	GHS08 GHS09 Wng	H361f H373 H410		M = 1 M = 1’
‘616-032-00-9	diflufenican (ISO); N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide; 2′,4′-difluoro-2-(α,α,α-trifluoro-m-tolyloxy) nicotinanilide	-	83164-33-4	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 10 000 M = 1 000 ’
‘616-106-00-0	phenmedipham (ISO); methyl 3-(3-methylcarbaniloyloxy)carbanilate	237-199-0	13684-63-4	Aquatic Acute 1 Aquatic Chronic 1	H400 H410	GHS09 Wng	H410		M = 10 M = 10’
‘616-113-00-9	desmedipham (ISO); ethyl 3-phenylcarbamoyloxyphenylcarbamate	237-198-5	13684-56-5	Repr. 2 Aquatic Acute 1 Aquatic Chronic 1	H361d H400 H410	GHS08 GHS09 Wng	H361d H410		M = 10 M = 10’

(3) the entry corresponding to index number 015-192-00-1 is deleted.

Reading this document does not replace reading the official text published in the Official Journal of the European Union. We assume no responsibility for any inaccuracies arising from the conversion of the original to this format.

This text is published under EUR-Lex's own terms of reuse, not a Legalize or public-domain licence. EUR-Lex
Creative Commons Attribution 4.0 International (CC BY 4.0)
© European Union, https://eur-lex.europa.eu — Source: EUR-Lex (Publications Office of the European Union). Reused under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Only EU legislation published in the printed Official Journal of the European Union is deemed authentic; consolidated texts are reproduced here for documentation purposes and have been reformatted to Markdown.